From ImmuneXcite Enlists Body’s First Defender for Immune Attack on Cancer:

Neutrophils and T cells with mAbXcite

Neutrophils and T cells with mAbXcite—

A description of the immune response generated by Lexington, MA-based ImmuneXcite’s “mAbXcite” technology.

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges
In vitro assays that tackle the challenges of in vitro hepatotoxicity assessment
Eurofins Discovery

Sponsored · Webinar
Using Enzyme Fragment Complementation (EFC) Technology to Quantify Reporter Gene Activity
Robust, sensitive, & easy-to-use cell-based, reporter gene assays to study signaling pathways
Eurofins DiscoverX

From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities

Xconomy on Demand

We offer a number of ways to subscribe for free!